secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001453687-24-000143
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian announces positive updated Phase 2b data for Descartes-08 in MG; Phase 3 AURORA on track for H1 2025
--------------------------------------------------------------------------------

- Descartes-08 showed 5.5-point average MG-ADL reduction at Month 4 (n=12); 33% reached minimum symptom expression at Month 6.
- Responses durable through Month 12: 80% (4/5) maintained clinically meaningful improvement.
- No CRS or ICANS reported; safety supports outpatient administration without lymphodepleting chemo.
- Phase 3 AURORA trial (n≈100) to begin H1 2025; primary endpoint: ≥3-point MG-ADL improvement vs placebo at Month 4.
- Retreated Phase 2a patients showed rapid responses again; no new safety signals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000143/0001453687-24-000143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000143/rnac-20241203.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer